Anthropic Acquires Coefficient Bio in $400 Mn Bet on AI-Driven Medical Research

Anthropic has reportedly acquired Coefficient Bio, a young startup focused on applying artificial intelligence to medical research, in a deal valued at over $400 million in stock.

The acquisition was disclosed through investor communication from Dimension, which held a significant stake in Coefficient. Founded just eight months ago by former pharmaceutical executives and researchers, the startup developed AI models tailored for biological research and decision-making.

Coefficient’s technology is aimed at accelerating complex research workflows, including small molecule discovery—a critical process in drug development. Small molecules form the foundation of most pharmaceuticals, and identifying viable candidates can be time-consuming due to the dynamic nature of biological structures. AI models can significantly speed up tasks such as molecular docking analysis, which determines how effectively a compound can interact with disease targets.

The acquisition aligns with Anthropic’s growing focus on scientific applications of AI. The company has recently enhanced its Claude models to better support medical research tasks and integrated them with clinical databases and research tools.

The move also comes amid intensifying competition in AI-driven research, with startups and tech giants alike investing in tools to accelerate drug discovery, biomarker analysis and protein mapping.

Industry players such as OpenAI are also advancing capabilities in automated research, further pushing innovation in the space.